MYL2 is a potential diagnostic, prognostic, and immune biomarker for HNSC

Abstract The significance of MYL2 as a possible HNSC treatment gene is unknown, the purpose of this study was to determine the exact involvement of MYL2 in HNSC.The Tumor Immune Estimate Resource (TIMER), UALCAN, The Cancer Genome Atlas (TCGA), and Gene Expression Omnibus (GEO) databases were used to assess MYL2 mRNA and protein expression levels in HNSC. Experimental tests, including immunohistochemistry, were used to corroborate the findings using HNSC tumor tissues and normal controls. Next, the prognostic effect of MYL2 on HNSC was analyzed using TCGA and GEPIA. Understanding MYL2 mutations in HNSC through the cBioPortal database. The metascape and CAMOIP datasets were also used to further understand MYL2's functional role. Finally, the effect of MYL2 on the immune microenvironment was examined by immune infiltration and monomolecular analysis.A poor prognosis often accompanies high MYL2 expression in HNSC. MYL2 can serve as an effective predictive biomarker for distinguishing HNSC from normal tissue, according to ROC studies. In addition, in HNSC, MYL2 is mainly affected by amplifying mutations. MYL2 may have a role in HNSC tumorigenesis and development via the calcium signaling route, the cGMP-PKG signaling pathway, and the interaction of ECM and receptors. Ultimately, we found that MYL2 influences the development of HNSC through the regulation of multiple immune cells. The findings show that MYL2 plays a crucial role in HNSC development and that it might be a potential independent prognostic biomarker and therapy target for HNSC.